Full Press Release Details
BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential In Two Rare Disease Indications At The European Society Of Gene And Cell Therapy Conference.
BBIO
BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential In Two Rare Disease Indications At The European Society Of Gene And Cell Therapy Conference
Key Takeaway: BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential In Two Rare Disease Indications At The European Society Of Gene And Cell Therapy Conference
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis